Inicio
Annals of Hepatology
|
Tipo de obra :
Autre
Naturaleza de la obra :
Oeuvre
|
Documentos disponibles con este título uniforme (9)
Clasificado(s) por (Año de edición descendente) Refinar búsquedaO-6 EXPLORING THE IMPACT OF INFECTIONS IN PATIENTS WITH ALCOHOL- ASSOCIATED HEPATITIS IN LATIN AMERICA / Juan Carlos Restrepo Gutiérrez
Título : O-6 EXPLORING THE IMPACT OF INFECTIONS IN PATIENTS WITH ALCOHOL- ASSOCIATED HEPATITIS IN LATIN AMERICA Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Autor Fecha de publicación : 2024 Títulos uniformes : Annals of Hepatology Idioma : Inglés (eng) Resumen : Introduction and Methods Severe alcohol-associated hepatitis (AH) is frequently associated with higher infection risk. This study aimed to assess the impact of infections in patients with AH in a multinational cohort in Latin America. Materials and Methods Multicenter prospective cohort study including patients with AH (2015-2022). We recorded clinical information, and the impact of infections was assessed using competing-risk models. Results We included 511 patients from 24 centers in 8 countries (Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, and Peru). The mean age was 50.1±11.9 years, 426 (83.9%) were men, 264 (58.2%) had a previous diagnosis of cirrhosis, and the median MELD at diagnosis was 24.6 [19.6–30.6] points. Out of the total, 25.9% died, and only 3.7% underwent liver transplantation during follow-up. Also, 44.5% of patients developed an infection. Of them, 50.9% presented with infection at admission, 30.8% developed an infection during hospitalization, and 18.3% presented an infection in both situations. The most common localizations at admission were pulmonary (32.4%), urinary tract (33.1%), spontaneous bacterial peritonitis (15.9%), and cutaneous (9.7%). The main localizations during hospitalization were pulmonary (34.4%), urinary tract (25.8%), spontaneous bacterial peritonitis (14.0%), and bacteremia (8.6%%). The incidence of multidrug-resistant (MDR) organisms was 11.2% at admission and 10.3% during hospitalization, while the incidence of extensively drug-resistant (XDR) organisms was 1.4% and 4.7%, respectively. The presence of infection was associated with higher mortality (sub-distribution hazard ratio [sHR] 1.92, 95%CI:1.56–2.37; p Mención de responsabilidad : Luis Antonio Díaz, Francisco Idalsoaga, Gustavo Ayares, Jorge Arnold, Katherine Maldonado, María Ayala, Diego Perez, Jaime Gomez, Rodrigo Escarate, Eduardo Fuentes, Juan Pablo Roblero, Blanca Norero, Raul Lazarte, José Antonio Velarde, Janett Jacobo, Jacqueline Córdova, Fátima Higuera-de-la-Tijera, Jesús Varela, Scherezada Mejía, Rita Silva, Cristina Melo, Roberta C. Araujo, Gustavo Henrique Pereira, Claudia Couto,fernando Bessone, Mario Tanno, Gustavo Romero, Manuel Mendizabal, Sebastián Marciano, Gonzalo Gomez,Melisa Dirchwolf, Pedro Montes, Patricia Guerra, Geraldine Ramos, Juan Carlos Restrepo, Enrique Carrera, Mayur Brahmania, Ashwani Singal, Ramón Bataller, Vijay Shah, Patrick S. Kamath,Marco Arrese,Juan Pablo Arab Referencia : Annals of Hepatology Volume 29, Supplement 1, February 2024, 101256 DOI (Digital Object Identifier) : 10.1016/j.aohep.2023.101256 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S1665268123003599 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis O-6 EXPLORING THE IMPACT OF INFECTIONS IN PATIENTS WITH ALCOHOL- ASSOCIATED HEPATITIS IN LATIN AMERICA [documento electrónico] / Juan Carlos Restrepo Gutiérrez, Autor . - 2024.
Obra : Annals of Hepatology
Idioma : Inglés (eng)
Resumen : Introduction and Methods Severe alcohol-associated hepatitis (AH) is frequently associated with higher infection risk. This study aimed to assess the impact of infections in patients with AH in a multinational cohort in Latin America. Materials and Methods Multicenter prospective cohort study including patients with AH (2015-2022). We recorded clinical information, and the impact of infections was assessed using competing-risk models. Results We included 511 patients from 24 centers in 8 countries (Argentina, Bolivia, Brazil, Chile, Colombia, Ecuador, Mexico, and Peru). The mean age was 50.1±11.9 years, 426 (83.9%) were men, 264 (58.2%) had a previous diagnosis of cirrhosis, and the median MELD at diagnosis was 24.6 [19.6–30.6] points. Out of the total, 25.9% died, and only 3.7% underwent liver transplantation during follow-up. Also, 44.5% of patients developed an infection. Of them, 50.9% presented with infection at admission, 30.8% developed an infection during hospitalization, and 18.3% presented an infection in both situations. The most common localizations at admission were pulmonary (32.4%), urinary tract (33.1%), spontaneous bacterial peritonitis (15.9%), and cutaneous (9.7%). The main localizations during hospitalization were pulmonary (34.4%), urinary tract (25.8%), spontaneous bacterial peritonitis (14.0%), and bacteremia (8.6%%). The incidence of multidrug-resistant (MDR) organisms was 11.2% at admission and 10.3% during hospitalization, while the incidence of extensively drug-resistant (XDR) organisms was 1.4% and 4.7%, respectively. The presence of infection was associated with higher mortality (sub-distribution hazard ratio [sHR] 1.92, 95%CI:1.56–2.37; p Mención de responsabilidad : Luis Antonio Díaz, Francisco Idalsoaga, Gustavo Ayares, Jorge Arnold, Katherine Maldonado, María Ayala, Diego Perez, Jaime Gomez, Rodrigo Escarate, Eduardo Fuentes, Juan Pablo Roblero, Blanca Norero, Raul Lazarte, José Antonio Velarde, Janett Jacobo, Jacqueline Córdova, Fátima Higuera-de-la-Tijera, Jesús Varela, Scherezada Mejía, Rita Silva, Cristina Melo, Roberta C. Araujo, Gustavo Henrique Pereira, Claudia Couto,fernando Bessone, Mario Tanno, Gustavo Romero, Manuel Mendizabal, Sebastián Marciano, Gonzalo Gomez,Melisa Dirchwolf, Pedro Montes, Patricia Guerra, Geraldine Ramos, Juan Carlos Restrepo, Enrique Carrera, Mayur Brahmania, Ashwani Singal, Ramón Bataller, Vijay Shah, Patrick S. Kamath,Marco Arrese,Juan Pablo Arab Referencia : Annals of Hepatology Volume 29, Supplement 1, February 2024, 101256 DOI (Digital Object Identifier) : 10.1016/j.aohep.2023.101256 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S1665268123003599 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002184 AC-2024-037 Archivo digital Producción Científica Artículos científicos Disponible
Título : O-7 CURRENT PRACTICE OF LIVER TRANSPLANTATION IN LATIN AMERICAN COUNTRIES: AN ALEH INTEREST GROUP SURVEY 2023 Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Autor Fecha de publicación : 2024 Títulos uniformes : Annals of Hepatology Idioma : Inglés (eng) Resumen : Introduction and Objectives Little is known about current practice of liver transplantation (LT) in Latin American countries (LATAM). This study aimed to describe LT activity, immunosuppression protocols and policies regarding prophylaxis of cytomegalovirus (CMV) infection and hepatitis B virus (HBV) recurrence in different active LATAM centers. Materials and Methods A web-based survey with 20 questions regarding LT practice was sent to all members of ALEH LT SIG in December 2022. Results 22 centers performing 35 [5-160] LT per year from Brazil (n=5), Argentina (n=4), Chile (n=4), Ecuador (n-2), Mexico (n=2), Colombia (n=1), Costa Rica (n=1), Peru (n=1), Dominican Republic (n=1) and Uruguay (n=1) answered the survey. Tacrolimus, mycophenolate and prednisone was the main immunosuppressive regimen employed by most (72%) centers and 81% of them referred basiliximab use for induction therapy in selected patients. Tailoring of immunosuppression was universally accepted, particularly in autoimmune hepatitis (AIH) (59%), hepatocellular carcinoma (54%) kidney dysfunction (77%) and primary biliary cirrhosis (33%). Weaning of corticosteroids at three, six and 12 months after LT was reported, respectively, by 41%, 36% and 23% of the centers, but policy for lifelong corticosteroid use in AIH-transplanted subjects was commonly observed (90%). Just four centers are currently performing protocol liver biopsies, while 18 of them are considering liver biopsy prior to steroid pulse therapy. HBIG and nucleos(t)ide analogs are used in most instances (73%) for HBV recurrence prevention, whereas CMV infection prophylaxis was shown to vary sharply across centers. Of note, all but two of them referred major changes in LT practice over the years due to economical restraints. Conclusions Compliance with standard of care recommendations for management of LT was reported by most centers. Heterogeneity in practices regarding HBV infection recurrence and CMV prophylaxis may reflect local financial restraints and point to the importance of developing ALEH guidelines to encourage LT activity in LATAM. Mención de responsabilidad : Paulo Bittencourt, Liana Codes, Adrian Gadano, Alejandra Villamil, Alfeu de Medeiros Fleck Jr, Álvaro Urzua, Debora Raquel Terrabuio, Eira Cerda, Graciela Elia Castro Narro, Ignacio Roca, John Abad González, Josefina Pages, Juan Carlos Restrepo Gutierrez, Leonardo de Lucca Schiavon, Mario Uribe, Martin Padilla, Norma Marlene Perez Figueroa, Pablo Coste Murillo, Raquel Stucchi, Ricardo Chong, Rodrigo Wolff, Victoria Mainardi, Rodrigo Zapata. Referencia : Annals of Hepatology Volume 29, Supplement 1, February 2024, 101257 DOI (Digital Object Identifier) : 10.1016/j.aohep.2023.101257 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S1665268123003605 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis O-7 CURRENT PRACTICE OF LIVER TRANSPLANTATION IN LATIN AMERICAN COUNTRIES: AN ALEH INTEREST GROUP SURVEY 2023 [documento electrónico] / Juan Carlos Restrepo Gutiérrez, Autor . - 2024.
Obra : Annals of Hepatology
Idioma : Inglés (eng)
Resumen : Introduction and Objectives Little is known about current practice of liver transplantation (LT) in Latin American countries (LATAM). This study aimed to describe LT activity, immunosuppression protocols and policies regarding prophylaxis of cytomegalovirus (CMV) infection and hepatitis B virus (HBV) recurrence in different active LATAM centers. Materials and Methods A web-based survey with 20 questions regarding LT practice was sent to all members of ALEH LT SIG in December 2022. Results 22 centers performing 35 [5-160] LT per year from Brazil (n=5), Argentina (n=4), Chile (n=4), Ecuador (n-2), Mexico (n=2), Colombia (n=1), Costa Rica (n=1), Peru (n=1), Dominican Republic (n=1) and Uruguay (n=1) answered the survey. Tacrolimus, mycophenolate and prednisone was the main immunosuppressive regimen employed by most (72%) centers and 81% of them referred basiliximab use for induction therapy in selected patients. Tailoring of immunosuppression was universally accepted, particularly in autoimmune hepatitis (AIH) (59%), hepatocellular carcinoma (54%) kidney dysfunction (77%) and primary biliary cirrhosis (33%). Weaning of corticosteroids at three, six and 12 months after LT was reported, respectively, by 41%, 36% and 23% of the centers, but policy for lifelong corticosteroid use in AIH-transplanted subjects was commonly observed (90%). Just four centers are currently performing protocol liver biopsies, while 18 of them are considering liver biopsy prior to steroid pulse therapy. HBIG and nucleos(t)ide analogs are used in most instances (73%) for HBV recurrence prevention, whereas CMV infection prophylaxis was shown to vary sharply across centers. Of note, all but two of them referred major changes in LT practice over the years due to economical restraints. Conclusions Compliance with standard of care recommendations for management of LT was reported by most centers. Heterogeneity in practices regarding HBV infection recurrence and CMV prophylaxis may reflect local financial restraints and point to the importance of developing ALEH guidelines to encourage LT activity in LATAM. Mención de responsabilidad : Paulo Bittencourt, Liana Codes, Adrian Gadano, Alejandra Villamil, Alfeu de Medeiros Fleck Jr, Álvaro Urzua, Debora Raquel Terrabuio, Eira Cerda, Graciela Elia Castro Narro, Ignacio Roca, John Abad González, Josefina Pages, Juan Carlos Restrepo Gutierrez, Leonardo de Lucca Schiavon, Mario Uribe, Martin Padilla, Norma Marlene Perez Figueroa, Pablo Coste Murillo, Raquel Stucchi, Ricardo Chong, Rodrigo Wolff, Victoria Mainardi, Rodrigo Zapata. Referencia : Annals of Hepatology Volume 29, Supplement 1, February 2024, 101257 DOI (Digital Object Identifier) : 10.1016/j.aohep.2023.101257 Derechos de uso : CC BY-NC-ND En línea : https://www.sciencedirect.com/science/article/pii/S1665268123003605 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD002185 AC-2024-038 Archivo digital Producción Científica Artículos científicos Disponible 
Título : Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2020 Títulos uniformes : Annals of Hepatology Idioma : Inglés (eng) Palabras clave : Steatosis NAFLD NASH Fatty liver Clinical practice guidance Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis MAFLD Cirrhosis Resumen : Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20–30% of the general population. Furthermore, its prevalence is predicted to increase exponentially in the next decades, concomitantly with the global epidemic of obesity, type 2 diabetes mellitus (T2DM), and sedentary lifestyle. NAFLD is a clinical syndrome that encompasses a wide spectrum of associated diseases and hepatic complications such as hepatocellular carcinoma (HCC). Moreover, this disease is believed to become the main indication for liver transplantation in the near future. Since NAFLD management represents a growing challenge for primary care physicians, the Asociación Latinoamericana para el Estudio del Hígado (ALEH) has decided to organize this Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease, written by Latin-American specialists in different clinical areas, and destined to general practitioners, internal medicine specialists, endocrinologists, diabetologists, gastroenterologists, and hepatologists. The main purpose of this document is to improve patient care and awareness of NAFLD. The information provided in this guidance may also be useful in assisting stakeholders in the decision-making process related to NAFLD. Since new evidence is constantly emerging on different aspects of the disease, updates to this guideline will be required in future. Mención de responsabilidad : Juan Pablo Arab, Melisa Dirchwolf, Mário Reis Álvares-da-Silva, Francisco Barrera, Carlos Benítez, Marlene Castellanos-Fernandez, Graciela Castro-Narro, Norberto Chavez-Tapia, Daniela Chiodi, Helma Cotrim, Kenneth Cusi, Claudia Pinto Marques Souza de Oliveira, Javier Díaz, Eduardo Fassio, Solange Gerona, Marcos Girala, Nelia Hernandez, Sebastián Marciano, Walter Masson, Nahum Méndez-Sánchez, Nathalie Leite, Adelina Lozano, Martín Padilla, Arturo Panduro, Raymundo Paraná, Edison Parise, Marlene Perez, Jaime Poniachik, Juan Carlos Restrepo, Andrés Ruf, Marcelo Silva, Martín Tagle, Monica Tapias, Kenia Torres, Eduardo Vilar-Gomez, José Eduardo Costa Gil, Adrian Gadano, Marco Arrese Referencia : Ann Hepatol. Nov-Dec 2020;19(6):674-690. DOI (Digital Object Identifier) : 10.1016/j.aohep.2020.09.006 PMID : 33031970 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1665268120301770 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Latin American Association for the study of the liver (ALEH) practice guidance for the diagnosis and treatment of non-alcoholic fatty liver disease [documento electrónico] / Juan Carlos Restrepo Gutiérrez, . - 2020.
Obra : Annals of Hepatology
Idioma : Inglés (eng)
Palabras clave : Steatosis NAFLD NASH Fatty liver Clinical practice guidance Nonalcoholic fatty liver disease Nonalcoholic steatohepatitis MAFLD Cirrhosis Resumen : Non-alcoholic fatty liver disease (NAFLD) currently represents an epidemic worldwide. NAFLD is the most frequently diagnosed chronic liver disease, affecting 20–30% of the general population. Furthermore, its prevalence is predicted to increase exponentially in the next decades, concomitantly with the global epidemic of obesity, type 2 diabetes mellitus (T2DM), and sedentary lifestyle. NAFLD is a clinical syndrome that encompasses a wide spectrum of associated diseases and hepatic complications such as hepatocellular carcinoma (HCC). Moreover, this disease is believed to become the main indication for liver transplantation in the near future. Since NAFLD management represents a growing challenge for primary care physicians, the Asociación Latinoamericana para el Estudio del Hígado (ALEH) has decided to organize this Practice Guidance for the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease, written by Latin-American specialists in different clinical areas, and destined to general practitioners, internal medicine specialists, endocrinologists, diabetologists, gastroenterologists, and hepatologists. The main purpose of this document is to improve patient care and awareness of NAFLD. The information provided in this guidance may also be useful in assisting stakeholders in the decision-making process related to NAFLD. Since new evidence is constantly emerging on different aspects of the disease, updates to this guideline will be required in future. Mención de responsabilidad : Juan Pablo Arab, Melisa Dirchwolf, Mário Reis Álvares-da-Silva, Francisco Barrera, Carlos Benítez, Marlene Castellanos-Fernandez, Graciela Castro-Narro, Norberto Chavez-Tapia, Daniela Chiodi, Helma Cotrim, Kenneth Cusi, Claudia Pinto Marques Souza de Oliveira, Javier Díaz, Eduardo Fassio, Solange Gerona, Marcos Girala, Nelia Hernandez, Sebastián Marciano, Walter Masson, Nahum Méndez-Sánchez, Nathalie Leite, Adelina Lozano, Martín Padilla, Arturo Panduro, Raymundo Paraná, Edison Parise, Marlene Perez, Jaime Poniachik, Juan Carlos Restrepo, Andrés Ruf, Marcelo Silva, Martín Tagle, Monica Tapias, Kenia Torres, Eduardo Vilar-Gomez, José Eduardo Costa Gil, Adrian Gadano, Marco Arrese Referencia : Ann Hepatol. Nov-Dec 2020;19(6):674-690. DOI (Digital Object Identifier) : 10.1016/j.aohep.2020.09.006 PMID : 33031970 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1665268120301770 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001591 AC-2020-097 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2020-097.pdfAdobe Acrobat PDF
Título : Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH) Tipo de documento : documento electrónico Autores : Juan Carlos Restrepo Gutiérrez, Fecha de publicación : 2019 Títulos uniformes : Annals of Hepatology Idioma : Inglés (eng) Palabras clave : Alcohol alcohol use disorder alcohol-related liver disease alcoholic hepatitis alcoholic liver disease cirrhosis clinical practice guidelines corticosteroids Resumen : Alcohol-related liver disease (ALD) is a major cause of advanced chronic liver disease in Latin-America, although data on prevalence is limited. Public health policies aimed at reducing the alarming prevalence of alcohol use disorder in Latin-America should be implemented. ALD comprises a clinical-pathological spectrum that ranges from steatosis, steatohepatitis to advanced forms such as alcoholic hepatitis (AH), cirrhosis and hepatocellular carcinoma. Besides genetic factors, the amount of alcohol consumption is the most important risk factor for the development of ALD. Continuous consumption of more than 3 standard drinks per day in men and more than 2 drinks per day in women increases the risk of developing liver disease. The pathogenesis of ALD is only partially understood and recent translational studies have identified novel therapeutic targets. Early forms of ALD are often missed and most clinical attention is focused on AH, which is defined as an abrupt onset of jaundice and liver-related complications. In patients with potential confounding factors, a transjugular biopsy is recommended. The standard therapy for AH (i.e. prednisolone) has not evolved in the last decades yet promising new therapies (i.e. G-CSF, N-acetylcysteine) have been recently proposed. In both patients with early and severe ALD, prolonged abstinence is the most efficient therapeutic measure to decrease long-term morbidity and mortality. A multidisciplinary team including alcohol addiction specialists is recommended to manage patients with ALD. Liver transplantation should be considered in the management of patients with end-stage ALD that do not recover despite abstinence. In selected cases, increasing number of centers are proposing early transplantation for patients with severe AH not responding to medical therapy. Mención de responsabilidad : Juan P Arab, Juan P Roblero, Jose Altamirano, Fernando Bessone, Roberta Chaves Araujo, Fatima Higuera-De la Tijera, Juan Carlos Restrepo, Aldo Torre, Alvaro Urzua, Douglas A Simonetto, Juan G Abraldes, Nahum Méndez-Sánchez, Fernando Contreras, Michael R Lucey, Vijay H Shah, Helena Cortez-Pinto, Ramon Bataller Referencia : Ann Hepatol. 2019 May - Jun;18(3):518-535 DOI (Digital Object Identifier) : 10.1016/j.aohep.2019.04.005 PMID : 31053546 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1665268119300419 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Alcohol-related liver disease: Clinical practice guidelines by the Latin American Association for the Study of the Liver (ALEH) [documento electrónico] / Juan Carlos Restrepo Gutiérrez, . - 2019.
Obra : Annals of Hepatology
Idioma : Inglés (eng)
Palabras clave : Alcohol alcohol use disorder alcohol-related liver disease alcoholic hepatitis alcoholic liver disease cirrhosis clinical practice guidelines corticosteroids Resumen : Alcohol-related liver disease (ALD) is a major cause of advanced chronic liver disease in Latin-America, although data on prevalence is limited. Public health policies aimed at reducing the alarming prevalence of alcohol use disorder in Latin-America should be implemented. ALD comprises a clinical-pathological spectrum that ranges from steatosis, steatohepatitis to advanced forms such as alcoholic hepatitis (AH), cirrhosis and hepatocellular carcinoma. Besides genetic factors, the amount of alcohol consumption is the most important risk factor for the development of ALD. Continuous consumption of more than 3 standard drinks per day in men and more than 2 drinks per day in women increases the risk of developing liver disease. The pathogenesis of ALD is only partially understood and recent translational studies have identified novel therapeutic targets. Early forms of ALD are often missed and most clinical attention is focused on AH, which is defined as an abrupt onset of jaundice and liver-related complications. In patients with potential confounding factors, a transjugular biopsy is recommended. The standard therapy for AH (i.e. prednisolone) has not evolved in the last decades yet promising new therapies (i.e. G-CSF, N-acetylcysteine) have been recently proposed. In both patients with early and severe ALD, prolonged abstinence is the most efficient therapeutic measure to decrease long-term morbidity and mortality. A multidisciplinary team including alcohol addiction specialists is recommended to manage patients with ALD. Liver transplantation should be considered in the management of patients with end-stage ALD that do not recover despite abstinence. In selected cases, increasing number of centers are proposing early transplantation for patients with severe AH not responding to medical therapy. Mención de responsabilidad : Juan P Arab, Juan P Roblero, Jose Altamirano, Fernando Bessone, Roberta Chaves Araujo, Fatima Higuera-De la Tijera, Juan Carlos Restrepo, Aldo Torre, Alvaro Urzua, Douglas A Simonetto, Juan G Abraldes, Nahum Méndez-Sánchez, Fernando Contreras, Michael R Lucey, Vijay H Shah, Helena Cortez-Pinto, Ramon Bataller Referencia : Ann Hepatol. 2019 May - Jun;18(3):518-535 DOI (Digital Object Identifier) : 10.1016/j.aohep.2019.04.005 PMID : 31053546 Derechos de uso : CC BY-NC-ND En línea : https://linkinghub.elsevier.com/retrieve/pii/S1665268119300419 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD001229 AC-2019-018 Archivo digital Producción Científica Artículos científicos Disponible Documentos electrónicos
2019-018.pdfAdobe Acrobat PDF
Título : Results of Liver Transplantation for Hepatocellular Carcinoma in a Multicenter Latin American Cohort Study Tipo de documento : documento electrónico Autores : Sergio Iván Hoyos Duque, Fecha de publicación : 2018 Títulos uniformes : Annals of Hepatology Idioma : Inglés (eng) Palabras clave : Liver cancer prediction candidate selection. Resumen : Background and aims: Heterogeneous data has been reported regarding liver transplantation (LT) for hepatocellular carcinoma (HCC) in Latin America. We aimed to describe treatment during waiting list, survival and recurrence of HCC after LT in a multicenter study from Latin America. Material and methods: Patients with HCC diagnosed prior to transplant (cHCC) and incidentally found in the explanted liver (iHCC) were included. Imaging-explanted features were compared in cHCC (non-discordant if pre and post-LT were within Milan, discordant if pre-LT was within and post-LT exceeding Milan). Results: Overall, 435 patients with cHCC and 92 with iHCC were included. At listing, 81% and 91% of cHCC patients were within Milan and San Francisco criteria (UCSF), respectively. Five-year survival and recurrence rates for cHCC within Milan, exceeding Milan/within UCSF and beyond UCSF were 71% and 16%; 66% and 26%; 46% and 55%, respectively. Locoregional treatment prior to LT was performed in 39% of cHCC within Milan, in 53% beyond Milan/within UCSF and in 83% exceeding UCSF (p 1,000 ng/mL 64%; p = 0.12). Discordant imaging-explanted data was observed in 29% of cHCC, showing lower survival HR 2.02 (CI 1.29; 3.15) and higher recurrence rates HR 2.34 when compared to AFP 1,000 ng/mL at listing was independently associated with a higher 5-year recurrence rate and a HR of 3.24 when compared to AFP Mención de responsabilidad : Federico Piñero, Paulo Costa, Yuri L Boteon, Sergio Hoyos Duque, Sebastian Marciano, Margarita Anders, Adriana Varón, Alina Zerega, Jaime Poniachik, Alejandro Soza, Martín Padilla Machaca, Josemaría Menéndez, Rodrigo Zapata, Mario Vilatoba, Linda Muñoz, Martín Maraschio, Martín Fauda, Lucas McCormack, Adrian Gadano, Ilka Sf Boin, Jose H Parente García, Marcelo Silva Referencia : Ann Hepatol. 2018 Mar 1;17(2):256-267. DOI (Digital Object Identifier) : 10.5604/01.3001.0010.8648 PMID : 29469048 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1665268119301589 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Results of Liver Transplantation for Hepatocellular Carcinoma in a Multicenter Latin American Cohort Study [documento electrónico] / Sergio Iván Hoyos Duque, . - 2018.
Obra : Annals of Hepatology
Idioma : Inglés (eng)
Palabras clave : Liver cancer prediction candidate selection. Resumen : Background and aims: Heterogeneous data has been reported regarding liver transplantation (LT) for hepatocellular carcinoma (HCC) in Latin America. We aimed to describe treatment during waiting list, survival and recurrence of HCC after LT in a multicenter study from Latin America. Material and methods: Patients with HCC diagnosed prior to transplant (cHCC) and incidentally found in the explanted liver (iHCC) were included. Imaging-explanted features were compared in cHCC (non-discordant if pre and post-LT were within Milan, discordant if pre-LT was within and post-LT exceeding Milan). Results: Overall, 435 patients with cHCC and 92 with iHCC were included. At listing, 81% and 91% of cHCC patients were within Milan and San Francisco criteria (UCSF), respectively. Five-year survival and recurrence rates for cHCC within Milan, exceeding Milan/within UCSF and beyond UCSF were 71% and 16%; 66% and 26%; 46% and 55%, respectively. Locoregional treatment prior to LT was performed in 39% of cHCC within Milan, in 53% beyond Milan/within UCSF and in 83% exceeding UCSF (p 1,000 ng/mL 64%; p = 0.12). Discordant imaging-explanted data was observed in 29% of cHCC, showing lower survival HR 2.02 (CI 1.29; 3.15) and higher recurrence rates HR 2.34 when compared to AFP 1,000 ng/mL at listing was independently associated with a higher 5-year recurrence rate and a HR of 3.24 when compared to AFP Mención de responsabilidad : Federico Piñero, Paulo Costa, Yuri L Boteon, Sergio Hoyos Duque, Sebastian Marciano, Margarita Anders, Adriana Varón, Alina Zerega, Jaime Poniachik, Alejandro Soza, Martín Padilla Machaca, Josemaría Menéndez, Rodrigo Zapata, Mario Vilatoba, Linda Muñoz, Martín Maraschio, Martín Fauda, Lucas McCormack, Adrian Gadano, Ilka Sf Boin, Jose H Parente García, Marcelo Silva Referencia : Ann Hepatol. 2018 Mar 1;17(2):256-267. DOI (Digital Object Identifier) : 10.5604/01.3001.0010.8648 PMID : 29469048 En línea : https://linkinghub.elsevier.com/retrieve/pii/S1665268119301589 Enlace permanente : https://hospitalpablotobon.cloudbiteca.com/pmb/opac_css/index.php?lvl=notice_dis Reserva
Reservar este documento
Ejemplares(1)
Código de barras Número de Ubicación Tipo de medio Ubicación Sección Estado DD000802 AC-2018-089 Archivo digital Producción Científica Artículos científicos Disponible
Permalink
Permalink
Permalink
Permalink
